Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for liver cancer: triple therapy shows promise

NCT ID NCT05665348

Completed Disease control Sponsor: Federation Francophone de Cancerologie Digestive Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a third drug, ipilimumab, to the standard two-drug combination (atezolizumab and bevacizumab) improves survival and tumor shrinkage in people with advanced liver cancer. About 229 patients will receive either the standard two drugs or all three. The goal is to see if the triple therapy works better for those who cannot have surgery or other local treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ipilimumab (added to atezolizumab and bevacizumab)
What this could lead to
If successful, this could offer a more effective first-line treatment option for advanced liver cancer, potentially extending survival.
What could go wrong
This is a phase II-III trial, so results are not yet conclusive. Adding ipilimumab may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma metastatic malignant neoplasm metastatic neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA METASTATIC CANCER METASTATIC TUMOR

Contacts and locations

Locations

  • CAC Eugène Marquis

    Rennes, France

  • CAC Gustave Roussy

    Villejuif, France

  • CAC Paoli Calmettes

    Marseille, France

  • CH HCC

    Colmar, France

  • CH Saint-Jean

    Perpignan, France

  • CHD Vendée

    La Roche-sur-Yon, France

  • CHRU Hôpitaux de Tours

    Tours, France

  • CHU

    Angers, France

  • CHU Hôtel Dieu

    Nantes, France

  • CHU Robert Debré

    Reims, France

  • Cac Icans

    Strasbourg, France

  • Centre Hospitalier

    Cholet, France

  • Centre Hospitalier

    Pau, France

  • Centre Hospitalier

    Quimper, France

  • Centre Hospitalier

    St-Malo, France

  • Centre Hospitalier

    Valence, France

  • Ch Annecy Genevois

    Pringy, France

  • Ch Duchenne

    Boulogne-sur-Mer, France

  • Chu Amiens Picardie

    Amiens, France

  • Chu Avicienne

    Bobigny, France

  • Chu Beaujon

    Clichy, France

  • Chu Brabois

    Vandœuvre-lès-Nancy, France

  • Chu Charles Nicolle

    Rouen, France

  • Chu Dupuytren

    Limoges, France

  • Chu Estaing

    Clermont-Ferrand, France

  • Chu Francois Mitterand

    Dijon, France

  • Chu Haut Leveque

    Pessac, France

  • Chu Haut-Leveque

    Pessac, France

  • Chu L'Archet

    Nice, France

  • Chu La Croix Rousse

    Lyon, France

  • Chu La Miletrie

    Poitiers, France

  • Chu La Pitie Salpetriere

    Paris, France

  • Chu La Timone

    Marseille, France

  • Chu Morvan

    Brest, France

  • Chu Rangueil

    Toulouse, France

  • Chu Saint Antoine

    Paris, France

  • Chu Saint-Eloi

    Montpellier, France

  • Chu Saint-Etienne

    Saint-Priest-en-Jarez, France

  • Privé Bordeaux Nord

    Bordeaux, France

  • Privé CONFLUENT

    Nantes, France

  • Privé HPCA

    Plérin, France

  • Privé LES BONNETTES

    Arras, France

  • Privé Saint-Joseph

    Marseille, France

  • Privé Saint-Joseph

    Paris, France

  • Privé Sainte Anne

    Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.